Abstract:Dry eye disease (DED) is a common disease, and have an adverse effect the physical, functional, and psychological quality of life. It is a multifactorial disorder characterized by the loss of tear film homeostasis, in which self-perpetuating vicious cycle leads to deterioration of function and inflammation of the lacrimal functional unit. Hence, treatment strategies should be aimed at the interruption of the vicious inflammatory cycle and alleviation of ocular surface inflammation. Anti-inflammatory therapies … Show more
“…Clinical studies showed that the type of fatty acid intake affects the course of the disease ( Hu et al, 2002 ). As an indispensable part of people’s daily diet, fatty acids have increasingly become the focus of researches ( Manson et al, 2020 ; Farukhi et al, 2021 ; Hyon and Han, 2021 ). n-3 fatty acids are one type of long-chain polyunsaturated fatty acids (LCPUFAs).…”
BackgroundMultiple sclerosis is a chronic demyelinating disease of uncertain etiology. Traditional treatment methods produce more adverse effects. Epidemiological and clinical treatment findings showed that unknown environmental factors contribute to the etiology of MS and that diet is a commonly assumed factor. Despite the huge interest in diet expressed by people with MS and the potential role diet plays in MS, very little data is available on the role of diet in MS pathogenesis and MS course, in particular, studies on fats and MS. The oil of Acer truncatum is potential as a resource to be exploited in the treatment of some neurodegenerative diseases.ObjectiveHere, we investigated the underlying influences of Acer truncatum oil on the stimulation of remyelination in a cuprizone mouse model of demyelination.MethodsCuprizone (0.2% in chow) was used to establish a mouse model of demyelination. Acer truncatum oil was administrated to mice during remyelination. Following techniques were used: behavioral test, histochemistry, fluorescent immunohistochemistry, transmission electron microscope.ResultsMice exposed to cuprizone for 6 weeks showed schizophrenia-like behavioral changes, the increased exploration of the center in the open field test (OFT), increased entries into the open arms of the elevated plus-maze, as well as demyelination in the corpus callosum. After cuprizone withdrawal, the diet therapy was initiated with supplementation of Acer truncatum oil for 2 weeks. As expected, myelin repair was greatly enhanced in the demyelinated regions with increased mature oligodendrocytes (CC1) and myelin basic protein (MBP). More importantly, the supplementation with Acer truncatum oil in the diet reduced the schizophrenia-like behavior in the open field test (OFT) and the elevated plus-maze compared to the cuprizone recovery group. The results revealed that the diet supplementation with Acer truncatum oil improved behavioral abnormalities, oligodendrocyte maturation, and remyelination in the cuprizone model during recovery.ConclusionDiet supplementation with Acer truncatum oil attenuates demyelination induced by cuprizone, indicating that Acer truncatum oil is a novel therapeutic diet in demyelinating diseases.
“…Clinical studies showed that the type of fatty acid intake affects the course of the disease ( Hu et al, 2002 ). As an indispensable part of people’s daily diet, fatty acids have increasingly become the focus of researches ( Manson et al, 2020 ; Farukhi et al, 2021 ; Hyon and Han, 2021 ). n-3 fatty acids are one type of long-chain polyunsaturated fatty acids (LCPUFAs).…”
BackgroundMultiple sclerosis is a chronic demyelinating disease of uncertain etiology. Traditional treatment methods produce more adverse effects. Epidemiological and clinical treatment findings showed that unknown environmental factors contribute to the etiology of MS and that diet is a commonly assumed factor. Despite the huge interest in diet expressed by people with MS and the potential role diet plays in MS, very little data is available on the role of diet in MS pathogenesis and MS course, in particular, studies on fats and MS. The oil of Acer truncatum is potential as a resource to be exploited in the treatment of some neurodegenerative diseases.ObjectiveHere, we investigated the underlying influences of Acer truncatum oil on the stimulation of remyelination in a cuprizone mouse model of demyelination.MethodsCuprizone (0.2% in chow) was used to establish a mouse model of demyelination. Acer truncatum oil was administrated to mice during remyelination. Following techniques were used: behavioral test, histochemistry, fluorescent immunohistochemistry, transmission electron microscope.ResultsMice exposed to cuprizone for 6 weeks showed schizophrenia-like behavioral changes, the increased exploration of the center in the open field test (OFT), increased entries into the open arms of the elevated plus-maze, as well as demyelination in the corpus callosum. After cuprizone withdrawal, the diet therapy was initiated with supplementation of Acer truncatum oil for 2 weeks. As expected, myelin repair was greatly enhanced in the demyelinated regions with increased mature oligodendrocytes (CC1) and myelin basic protein (MBP). More importantly, the supplementation with Acer truncatum oil in the diet reduced the schizophrenia-like behavior in the open field test (OFT) and the elevated plus-maze compared to the cuprizone recovery group. The results revealed that the diet supplementation with Acer truncatum oil improved behavioral abnormalities, oligodendrocyte maturation, and remyelination in the cuprizone model during recovery.ConclusionDiet supplementation with Acer truncatum oil attenuates demyelination induced by cuprizone, indicating that Acer truncatum oil is a novel therapeutic diet in demyelinating diseases.
“…The number of registered randomized clinical trials about the effect of omega-3 fatty acids in DED (according to the search conducted in January 2024 in the ClinicalTrials.org registry) is 34. The majority of randomized clinical trials that are analyzed in available systematic reviews and/or metaanalysis support the efficacy of omega-3 fatty acid supplementation on the symptoms and progression of DED [34,54,55]. A more recent systematic-review and meta-analysis from 2023, found objective improvement in OSDI but not in other objective measures of DED like Schirmer's test.…”
Section: Systemic Effects Of Omega-3 Fatty Acids In Dry Eye Diseasementioning
As one of the most common diseases in ophthalmology today, dry eye disease (DED) poses a great challenge for public health systems globally. This is a multifactorial condition involving the production/evaporation of tears and consequential damage to the ocular surface. Symptoms of DED like discomfort and visual disturbance alter a person's quality of life and pose a significant economic burden to healthcare systems. Today's lifestyle favors DED development, especially long-term exposure to screens, poor sleep quality, and a diet abundant in saturated fats and omega-6 fatty acids, and we can expect that its prevalence will extend far beyond the currently estimated 10%. The underlying inflammation and symptoms of DED, are treated with various anti-inflammatory agents and autologous and/or allogeneic serum drops. Considering the role of lifestyle in DED pathophysiology, lifestyle modifications, including diet, sleep, and physical activity are getting more attention. Among them, supplementation with omega-3 fatty acids shows the most promising results in alleviating subjective and objective measures of DED through a direct effect on the stability and production of the tear film, inflammation markers, and corneal nerve regeneration. We aimed to provide insights into currently available research findings supporting omega-3 fatty acids as a valuable adjuvant therapy in treating DED.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.